ArticleJournal of medical case reports2025
Neoehrlichia mikurensis-associated secondary capillary leak syndrome and septic shock: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoehrlichiosis Causing Hemolytic Anemia in Patients Treated with Rituximab, Norway, 2024-2025.Emerging infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandidatus Neoehrlichians mikurensis is the agent of an emerging tick-borne zoonosis responsible for systemic inflammatory syndrome mainly in immunocompromised patients and in subjects with underlying hematological or immunological disorders. The reported clinical manifestations include fever, chills, night sweats, weight loss, skin rash, myalgia/arthralgia, and edema limited to the ankles, and the infection is associated with a high incidence of vascular events. We report an unusual case of neoeherlichiosis, diagnosed by means of broad-range eubacterial polymerase chain reaction assay from a sample of spontaneous psoas muscle hematoma, which presented with septic shock and secondary capillary leak syndrome. CASE PRESENTATION: A 58-year-old Caucasian Swiss woman undergoing treatment of rituximab presented after 8 weeks of fever, chills, night sweats, and diffuse edema resistant to recently introduced loop diuretics. The patient developed septic shock with anasarca, possibly due to secondary capillary leak syndrome. Extensive microbiological investigations identified Candidatus Neoehrlichia mikurensis from a sample of spontaneous psoas muscle hematoma using eubacterial polymerase chain reaction assay and in subsequent blood samples. The patient fully recovered after 3 weeks of antibiotic therapy with doxycycline.
conclusionThis case broadens the known clinical spectrum of the disease and may suggest a pathogenic role in hematoma formation, likely related to endothelial tropism and intravascular dissemination of the bacteria. Recognizing such atypical presentations is key to avoiding diagnostic delays. This case also highlights the diagnostic value of eubacterial polymerase chain reaction in emerging tick-borne infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.